GleamWall
中文EN

CTKB Cytek Biosciences, Inc.

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1831915 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.5%
TTM net income YoY-533.4%
TTM EPS YoY-519.7%
Revenue 3-yr CAGR4.3%
Net income 3-yr CAGR—

Margins

Gross margin54.7%
Operating margin-21.1%
Net margin-39.1%
FCF margin-6.5%
EBITDA margin-18.2%

Returns

ROE-23.2%
ROA-17.3%
ROIC (approx.)-12.8%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets28.0%
Debt / equity0.00x
Current ratio4.46x
Interest coverage-562.56x

Cash quality & payout

Operating cash flow / net income0.08x
Accruals ratio-15.9%
Payout ratio—
Capex / revenue3.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$201.49M$200.45M
Cost of revenue$97.03M$89.35M
Gross profit$104.46M$111.11M
R&D expense$36.47M$39.40M
SG&A expense$58.94M$43.11M
Operating income-$40.38M-$20.52M
Interest expense$474,000-$5.24M
Pretax income-$29.84M-$5.70M
Income tax$36.70M$320,000
Net income-$66.54M-$6.02M
EBITDA-$32.80M-$13.31M
EPS (diluted)——
Weighted avg. shares (diluted)127.75M130.61M
Balance sheet
Cash & equivalents$90.85M$98.75M
Receivables$62.51M$60.59M
Inventory$48.43M$43.89M
Current assets$392.00M$396.45M
PP&E, net$18.01M$17.96M
Goodwill$16.70M$16.66M
Intangibles$16.82M$20.13M
Total assets$461.54M$499.50M
Current liabilities$77.80M$67.66M
Total liabilities$119.80M$103.76M
Shareholders' equity$341.74M$395.74M
Shares outstanding128.55M129.21M
Cash flow statement
Operating cash flow-$4.69M$25.38M
Capital expenditure$4.08M$3.52M
Free cash flow-$8.77M$21.85M
Investing cash flow$10.12M-$82.97M
Financing cash flow-$13.43M-$15.82M
Depreciation & amortization$7.58M$7.21M
Stock-based compensation$24.59M$26.85M
Share buybacks$15.07M$21.61M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.